COL9A3

Across TCGA pan-cancer cohorts, COL9A3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated COL9A3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher COL9A3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated COL9A3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, READ, and COAD are the cancer types where COL9A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.826	.005	22	view →
READ	DFS	Median	All	0.082	0.799	<.001	15	view →
COAD	DFS	Median	All	0.175	0.699	<.001	11	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
SKCM	DFS	Median	III,IV	0.121	0.654	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

COL9A3–UCEC (DFS)

Open the UCEC breakdown →